This common prescription drug could reduce deaths by sepsis, study finds
Researchers set out to explore whether the cholesterol-busting drugs may bring additional benefits for patients.
The new study examined information on sepsis patients who received statins during a stint in intensive care and compared it with patients in a similar situation who did not receive statins.
Some 14.3 per cent of 6,000 sepsis patients who were given statins died within 28 days.
This is compared with 23.4 per cent of 6,000 patients who did not receive statin therapy.
The research team from China said that this equates to a 39 per cent reduced risk of death within a month.
The research, based on data from thousands of patients at a hospital in Israel between 2008 and 2019, also found that 7.4 per cent of statin patients died while in the intensive care unit compared with 13.6 per cent of those who did not receive statins.
And during their overall hospital stay, some 11.5 per cent of sepsis patients who were given statins died, compared with 19.1 per cent of sepsis patients who did not take statins.
However, it appeared that those who were not prescribed statins had a slightly shorter hospital stay compared with those who did receive them – an average of eight days compared with almost 10 days.
'We found that statin users exhibited decreased 28-day all-cause mortality,' the authors wrote in the journal Frontiers in Immunology.
Sepsis is a life-threatening reaction to an infection that occurs when the immune system overreacts and starts to damage the body's tissues and organs.
In the UK, 245,000 people are affected by sepsis every year.
UK sepsis experts said that 'anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored' as they called for larger trials to confirm the findings.
Statins are known as cholesterol-busting drugs because they can help lower the level of low-density lipoprotein (LDL) cholesterol in the blood.
But experts said that they also have other benefits, including reducing inflammation and antibacterial effects.
The research team called for larger trials to confirm their findings.
'Our large, matched cohort study found that treatment with statins was associated with a 39 per cent lower death rate for critically ill patients with sepsis, when measured over 28 days after hospital admission,' said Dr Caifeng Li, the study's corresponding author and an associate professor at Tianjin Medical University General Hospital in China.
'These results strongly suggest that statins may provide a protective effect and improve clinical outcomes for patients with sepsis.'
Commenting on the study, Dr Ron Daniels, founder and chief executive of the UK Sepsis Trust, said: 'It has been known for some time that the anti-inflammatory properties of statins confer a survival benefit on those who take them if they develop sepsis.
'Whilst previous studies have failed to show a similar survival benefit in treating people with sepsis with statins, this new study supports calls for a large, multi-country, randomised control trial.
'Anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Modern Flu Vaccines Provide Equal Protection for US Seniors
TOPLINE: During the 2022-2023 influenza season, an adjuvanted quadrivalent influenza vaccine (aQIV) and high-dose (HD) QIV showed comparable effectiveness at preventing test-confirmed influenza among US adults aged 65 years or older across all hospital settings. METHODOLOGY: Researchers conducted a retrospective study using the test-negative design to evaluate the effectiveness of the aQIV vs HD-QIV in preventing laboratory-confirmed influenza among US adults aged 65 years or older during the 2022-2023 influenza season. They analyzed data of 30,911 patients (mean age, 76.7 years) from a linked administrative claims database who had an acute respiratory or febrile illness, were tested for influenza within 7 days of diagnosis, and received either aQIV or HD-QIV. Patients who tested positive for influenza (n = 2361) were classified as cases, whereas those who tested negative (n = 28,550) were considered control individuals. The analysis was adjusted for demographic and clinical covariates, including insurance type, frailty index, healthcare utilization, comorbidities, and medical conditions associated with an increased risk for influenza complications. TAKEAWAY: Overall, 31.8% and 68.2% received the aQIV and HD-QIV, respectively, with comparable rates of test-positive influenza between groups during the observation period (7.2% and 7.9%, respectively). The relative vaccine effectiveness (rVE) of aQIV vs HD-QIV showed no significant difference across all settings (adjusted rVE, -2.5%; P = .631) and emergency department/inpatient settings (adjusted rVE, 0.0%; 95% CI, -15.9% to 13.7%). During the peak season (6 November to 24 December 2022), 13.6% of aQIV and 14.4% of HD-QIV recipients tested positive for influenza, and the rVE in the sensitivity analysis was consistent with that in the main analysis. IN PRACTICE: 'These findings align with current recommendations by ACIP [Advisory Committee on Immunization Practices] and other NITAGs [National Immunization Technical Advisory Groups] that support the use of adjuvanted and high-dose influenza vaccines in this age group,' the authors wrote. SOURCE: This study was led by Mahrukh Imran, CSL Seqirus, Kirkland, Quebec, Canada. It was published online on July 11, 2025, in International Journal of Infectious Diseases. LIMITATIONS: The observational study design introduced potential biases due to variability in the use of healthcare resources and heterogeneity inherent in the US healthcare system, which could not be fully accounted for. Vaccination was not randomized, and unmeasured confounding factors might have influenced the results. The limited sample size and data privacy constraints prevented a more detailed geographic analysis. Moreover, influenza testing was performed as part of routine care than according to preset screening criteria. DISCLOSURES: This study was supported by CSL Seqirus. Three authors reported being employees of CSL Seqirus and holding stock in CSL Limited. Three other authors reported being employees of Optum, which received funding from CSL Seqirus to support this work. One author reported receiving direct financial support from the study funders. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
an hour ago
- Yahoo
Chinese sub discovers deepest-ever creatures 10 km undersea
A Chinese submersible has discovered thousands of worms and molluscs nearly 10 kilometres (six miles) below sea level in the Mariana Trench, the deepest colony of creatures ever observed, a study revealed on Wednesday. The discovery in Earth's deepest underwater valley suggests that there could be much more life thriving in the hostile conditions at the bottom of our planet's largely unexplored oceans than previously thought, the China-led team of scientists said. Almost all life on Earth is supported by light from the Sun. However in the total darkness at the bottom of the world, these creatures live off of chemicals such as methane seeping through cracks in the seafloor, a process called chemosynthesis. Last year, the Chinese submersible "Fendouzhe" -- or "Striver" -- dove 23 times into the depths of the Mariana Trench in the western Pacific Ocean with researchers on board, according to the study in the journal Nature. They found colonies of thousands of marine tubeworms and molluscs called bivalves at depths ranging from 2,500 to 9,533 metres (8,200 to 31,000 feet) deep. Video released alongside the study showed fields of tubeworms, which grew up to 30 centimetres (12 inches) long, as well as piles of molluscs and clams. Spiky crustaceans, free-floating marine worms, sea cucumbers, feathery-armed sea lilies and other invertebrates were also recorded in the depths. The study marked "the discovery of the deepest and the most extensive chemosynthesis-based communities known to exist on Earth," its authors said. Given that other ocean trenches are similar, "such chemosynthesis-based communities might be more widespread than previously anticipated," they added. The researchers said they also found "compelling evidence" that methane was being produced by microbes, with the tubeworms tending to cluster around microbial mats that resemble snow. Previous studies have found thriving communities of single-cell organisms on the ocean floor, but few large animals. But a remotely operated vehicle discovered tubeworms and other marine invertebrates living in hydrothermal vents in the crust below the seafloor two kilometres deep in the Pacific, research said last year. - Pressure rising - The new study was published as nations wrangle over the contentious issue of deep-sea mining. China, the United States and others have expressed interest in mining the depths for valuable minerals. Ocean scientists warn that mining the little-explored seafloor, one of the last wild zones on the planet, could decimate fragile ecosystems that are not yet well understood. Despite recent talks, the International Seabed Authority -- which oversees deep-sea mining in international waters -- has yet to adopt long-awaited rules governing the industry. Chinese media has previously reported that the Fendouzhe submersible mission will conduct research on "deep-sea materials". Only a handful of people have ever visited the bottom of the Mariana Trench, which is a crescent-shaped depression in the Earth's crust that is deeper than Mount Everest is high. The first explorers visited the trench in 1960 on a brief expedition. But after that, there were no missions until Hollywood director James Cameron made the first solo trip to the bottom in 2012, describing a "desolate" and "alien" environment. The water pressure at the bottom of the trench is a crushing eight tons per square inch, more than a thousand times the atmospheric pressure at sea level. dl/jj
Medscape
an hour ago
- Medscape
GLP-1 Agonists for Type 2 Diabetes Reduce Psoriasis, HS Risk
TOPLINE: Treatment with glucagon like peptide 1 receptor agonist (GLP-1 RA) medications was associated with a lower risk of being diagnosed with hidradenitis suppurativa (HS) or psoriasis, in a study of patients with type 2 diabetes (T2D). METHODOLOGY: Researchers assessed 74,910 patients (mean age, 65 years; 56% women; 45% White and 23% Black individuals) with T2D from the All of Us Database between May 2018 and October 2023. Of all patients, 19.5% received GLP-1 RAs. The primary outcomes of the study were risks for HS and psoriasis, adjusted for effects on control of diabetes and weight loss. TAKEAWAY: Overall, 1601 patients had psoriasis (mean age, 68 years; 56.4% women; 62.4% White and 12.2% Black individuals), and 601 had HS (mean age, 55 years; 77.2% women; 32.9% White and 41.3% Black individuals). Patients treated with GLP-1 RAs showed a significantly lower risk for a future diagnosis of HS (adjusted odds ratio [OR], 0.61; P < .001) than those who were not treated with GLP-1 RAs. GLP-1 RA treatment was also associated with a significant reduction in the risk for a future diagnosis of psoriasis (adjusted OR, 0.41; P < .001). The average time from T2D diagnosis to a diagnosis of HS was 3.98 years and 3.44 years to a diagnosis of HS. IN PRACTICE: 'These findings support a protective effect against HS and psoriasis in patients with T2DM taking GLP-1 RAs independent of weight loss, smoking status, or glycemic control,' the study authors wrote. Based on these findings, they added, 'future research should focus on prospective studies exploring the use of GLP-1 RAs as therapeutic tools to treat HS or psoriasis, prevent disease progression, and evaluate their effect in patients without diabetes.' SOURCE: The study was led by Lauren M. Ching, Georgetown University School of Medicine, Washington, DC, and was published online on July 23, 2025, in JAAD International. LIMITATIONS: Limitations included variance in data harmonization across sites, lack of disease severity information, and selection bias. DISCLOSURES: The study did not receive any funding. One author reported receiving financial aids as an investigator, consultant, and speaker from AbbVie, BMS, Eli Lilly, and various other drug companies. All other authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
